BioCentury | May 28, 2020
Distillery Therapeutics

Epigenetic enzyme Tet1 as osteoarthritis target

...patient-derived chondrocytes, an shRNA against Tet1 reduced mRNA levels of two disease markers, MMP3 and MMP13...
...cartilage loss and MMP13 secretion. TARGET/MARKER/PATHWAY: Tet methylcytosine dioxygenase 1 (Tet1); matrix metalloproteinase 3 (MMP3); MMP13...
BioCentury | May 3, 2017
Distillery Therapeutics

Autoimmune disease

...senescent cells ( UBX0101 ) increased proliferation of healthy chondrocytes and decreased levels of matrix metalloproteinase 13 (MMP13...
...of an inducer of apoptosis in senescent cells decreased cartilage erosion and articular levels of MMP13...
...The Johns Hopkins University, Baltimore, Md. email: jhe@jhu.edu Hongjiang Li UBX0101 Johns Hopkins University Unity Biotechnology Inc. Interleukin-1 (IL-1) beta Matrix metalloproteinase 13 (MMP13...
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 13 (MMP13)

...Musculoskeletal disease INDICATION: Musculoskeletal Patient sample and mouse studies suggest inhibiting MMP13 could help treat bone...
...help treat bone loss in multiple myeloma (MM). In MM cells from patient bone marrow, MMP13...
...include identifying and inhibiting the MMP13 receptor that mediates bone loss in MM. TARGET/MARKER/PATHWAY: Matrix metalloproteinase 13 (MMP13...
BioCentury | Oct 23, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...and contact information Autoimmune disease Osteoarthritis Matrix metalloproteinase 13 (MMP13) In vitro and rat studies identified selective MMP13...
...screen and SAR studies identified a carboxylic acid compound that selectively inhibited the osteoarthritis-associated enzyme MMP13...
BioCentury | Jun 28, 2012
Strategy

Pharma compounds at the crossroads

...chronic myelogenous leukemia (CML) Pfizer SD-7300 (SC-81490) Inhibitor of matrix metalloproteinase 2 (MMP2), MMP9 and MMP13...
BioCentury | Dec 8, 2011
Cover Story

Big MAC attack in osteoarthritis

...CCL2 ), expression of additional C5 and secretion of ECM-degrading enzymes such as matrix metalloproteinase 13 (MMP13...
BioCentury | Sep 2, 2010
Distillery Therapeutics

Indication: Various

...MMP9; MMP13 In vitro and in vivo studies suggest that inhibitors of MMP2, MMP9 and MMP13...
...lead a-piperidinyl sulfones and one lead a-tetrahydropyranyl sulfone were subnanomolar inhibitors of MMP2, MMP9 and MMP13...
BioCentury | Jun 3, 2010
Cover Story

HIF2A: mastering osteoarthritis

...HIF2A in OA. In mouse cartilage cells, Hif2a activated matrix metalloproteinase 3 (Mmp3) , Mmp9, Mmp13...
BioCentury | Aug 6, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...Autoimmune disease Osteoarthritis Matrix metalloproteinase 13 (MMP13) In vitro and tissue studies suggest that selective inhibitors of MMP13...
...lead arylsulfonamide hydroxamate compound with low nanomolar activity against MMP13 and MMP2. The compound inhibited MMP13-induced...
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...a series of carboxylic acid inhibitors of MMP13 that could be useful for treating arthritis. MMP13...
...plays a role in degrading type II collagen in cartilage and bone. One compound inhibited MMP13...
...TACE), the inhibition of which can lead to side effects. In a rat model of MMP13-induced...
Items per page:
1 - 10 of 16